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A B S T R A C T
Background: Whether the prognosis of paradoxical low-gradient severe aortic stenosis (PLG-SAS),
especially due to paradoxical low-ﬂow low-gradient SAS (PLFLG-SAS), is malignant in any speciﬁc
ethnicity, including Japanese, remains unclear.
Methods: We retrospectively enrolled 385 consecutive Japanese patients (age, 76  8 years; 148 men)
with moderate AS [MAS: 0.6  indexed aortic valve area (iAVA) < 0.85 cm2/m2] or SAS (iAVA <0.6 cm2/m2)
with preserved left ventricular ejection fraction (50%). SAS patients were divided into PLG-SAS and high-
gradient (HG)-SAS according to the transvalvular mean gradient (40 mmHg). PLG-SAS was categorized into
2 groups: normal-ﬂow (NF) LG-SAS [stroke volume index (SVi) 35 mL/m2] and PLFLG-SAS (SVi <35 mL/m2).
Endpoints were all-cause death and major adverse cardio-cerebrovascular events (MACE).
Results: During a median follow-up of 15 months, 31 patients died and 48 suffered MACE. All-cause death
and MACE rates in PLG-SAS and PLFLG-SAS were signiﬁcantly lower than those in HG-SAS and similar to
those in MAS. On multivariate analysis, neither PLG-SAS nor PLFLG-SAS were independent determinants
for all-cause death compared with MAS [MAS as reference, PLG-SAS: hazard ratio (HR) 0.47, p = 0.32;
PLFLG-SAS: HR 0.01, p = 0.20; HG-SAS: HR 3.37, 95% conﬁdence interval 1.24–9.74, p = 0.02].
Conclusions: In Japanese patients, the prognoses of PLG-SAS and PLFLG-SAS were better than that of HG-
SAS and similar to that of MAS, being better than that in Western populations.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The severity of aortic stenosis (AS) is determined using well-
known echocardiographic criteria, including aortic valve area
(AVA), mean pressure gradient (mPG), and peak velocity across the
aortic valve [1]. However, some patients with severe AS (SAS) as
determined by AVA criteria and preserved left ventricular ejection* Corresponding author at: Second Department of Internal Medicine, University
of Occupational and Environmental Health, School of Medicine, 1-1 Iseigaoka,
Yahatanishi-ku, Kitakyushu 807-8555, Japan. Tel.: +81 93 691 7436;
fax: +81 93 691 6913.
E-mail address: takeuchi@med.uoeh-u.ac.jp (M. Takeuchi).
http://dx.doi.org/10.1016/j.jjcc.2014.12.019
0914-5087/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsfraction (LVEF) show a lower transvalvular gradient than expected
[1,2]. This discrepant severity, the so-called paradoxical low-
gradient SAS (PLG-SAS), appears to be related to a reduction in the
transvalvular ﬂow rate because of increased LV afterload and/or a
small LV.
The new entity, ‘‘paradoxical low-ﬂow, low-gradient’’ SAS
(PLFLG-SAS), deﬁned as having a stroke volume index (SVi)
<35 mL/m2, mPG <40 mmHg, and AVA <1.0 cm2 or indexed AVA
(iAVA) <0.6 cm2/m2with LVEF 50%, has gained clinical interest in
recent years [3–5]. Some North American and European studies
have demonstrated that the prognosis of medically treated PLFLG-
SAS is poor; therefore, prompt surgical intervention is recom-
mended [3–5]. However, other studies have shown that PLG-SAS
may have a relatively better outcome in European patients reserved.
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Nations reported that approximately 60% of the worldwide
population consists of Asians [8]. The prognoses of PLG-SAS and
PLFLG-SAS in populations of Asian descent have not been determined
thus far. This distinction is relevant because the prognoses of PLG-
SAS and PLFLG-SAS could differ according to race, stature, and
incidence of comorbidities. In particular, the smaller body size of
Japanese patients with AS may increase AVA-mPG discordance [9],
which could be associated with a different prognosis. Therefore, we
performed a multicenter study to determine the prognoses of PLG-
SAS and PLFLG-SAS in the Japanese population.
Methods
Patient population
From January 2008 to December 2012, we retrospectively
enrolled 663 consecutive Japanese AS patients with preserved LVEF
(LVEF >50%) from 4 cardiovascular centers [Gunma Prefectural
Cardiovascular Center (n = 187), University of Occupational and
Environmental Health (n = 254), University of Tsukuba (n = 122),
and St. Marianna University (n = 100)]. The ethics committee in
each hospital approved the study protocol. Patients with more than
mild concomitant aortic regurgitation, mitral stenosis, or mitral
regurgitation were excluded. Among the remaining patients, those
with mild AS (iAVA 0.85 cm2/m2) [10] were excluded. Thus, the
ﬁnal group consisted of 385 Japanese patients with moderate AS
(MAS: 0.6  iAVA < 0.85 cm2/m2) or SAS (iAVA <0.6 cm2/m2) with
preserved LVEF.
Demographic data collection
Clinical data, including age, gender, body surface area (BSA),
brachial blood pressure, and heart rate, documented diagnosis of
hypertension, dyslipidemia, diabetes mellitus, obesity [body mass
index (BMI), >30 kg/m2], and coronary artery disease (CAD), and
prior history of myocardial infarction or coronary artery bypass
grafting and hemodialysis for chronic renal failure, laboratory data
(brain natriuretic peptide, estimated glomerular ﬁltration rate,
hemoglobin concentration) and medication were collected at the
time of echocardiographic examination. We checked the patients’
symptomatic statuses using electronic medical records and
determined the presence of cardiac symptoms, including dyspnea
(New York Heart Association functional class II), chest pain
(Canadian Cardiovascular Society class I), and syncope. Follow-
up information was obtained regularly via outpatient clinics.
Patients, physicians, and next of kin were contacted by telephone if
the patients were treated at a different hospital.
Echocardiographic study
Comprehensive transthoracic echocardiography was per-
formed using commercially available ultrasound equipment
according to the American Society of Echocardiography (ASE)
guideline [11]. AVA was calculated by the continuity equation
using aortic valve jet velocity and LV outﬂow tract (LVOT) SV.
Aortic valve jet velocity was recorded from multiple acoustic
windows to yield the highest-velocity signal [1]. SV was
determined by the velocity–time integral by pulsed wave Doppler
echocardiography at LVOT  LV outﬂow area, which was deter-
mined by the following formula: 3.14  (LVOT diameter/2)2. LVOT
diameter was measured most carefully using the zoom mode of the
parasternal long-axis view in mid-systole from the black-white
interface of the septal endocardium to the anterior mitral leaﬂet,
parallel to the aortic plane and within 0.5–1.0 cm of the valve
oriﬁce. The LV end-diastolic volume and LVEF were measured bythe biplane Simpson’s method [11]. Relative wall thickness was
estimated as (2  diastolic LV posterior wall thickness)/LV end-
diastolic diameter [11]. LV mass was calculated using linear
measurement. According to the value of relative wall thickness and
LV mass index, patients were categorized into 4 types of LV
geometry: normal geometry, concentric remodeling, concentric
hypertrophy, and eccentric hypertrophy [11]. Maximum left atrial
(LA) volume was measured by the biplane Simpson’s method and
indexed to BSA [11]. Peak early and late diastolic velocity of LV
inﬂow (E and A velocity, respectively), deceleration time of E
velocity, and peak early diastolic velocity on the septal corner of the
mitral annulus (e’) were measured in the apical 4-chamber view
[12]. The diastolic dysfunction grade was determined in accordance
with ASE guidelines [12]. As a measure of global LV afterload,
valvulo-arterial impedance was determined using the following
formula: Zva = (SAP + mPG)/SVi, where SAP is the systolic arterial
pressure [5]. The energy loss coefﬁcient (ELCO) was determined as
follows: AVA  AA/(AA  AVA), where AA is the cross-sectional
area at the sinotubular junction [5]. ELCO was indexed to BSA.
AS grading according to ﬂow-pressure proﬁle
Based on the transvalvular mean gradient, SAS patients were
divided into PLG-SAS (mPG <40 mmHg) and high-gradient (HG)-
SAS (mPG 40 mmHg). PLG-SAS was also categorized into
2 subsets as normal-ﬂow (NF) LG-SAS (SVi 35 mL/m2) and
PLFLG-SAS (SVi <35 mL/m2).
Study endpoints
The primary study endpoint was all-cause death. The secondary
endpoint was the occurrence of major cardio-cerebrovascular
events (MACE) deﬁned as cardiac death, nonfatal myocardial
infarction, hospitalization for heart failure, stroke, and ventricular
tachyarrhythmia. Individuals were censored from the survival
analysis of all-cause death and MACE if they underwent aortic
valve replacement (AVR) in order to assess the natural history of
PLG-SAS and PLFLG-SAS.
Statistical analysis
Results are expressed as mean  standard deviation (SD) or
percentage unless otherwise speciﬁed. Data were compared between
patients developing a predeﬁned event and those without an event
using Student’s t-test, chi-square test, or Fisher’s exact test, as
appropriate. Comparisons among the 3 or 4 deﬁned AS subgroups
were performed using one-way analysis of variance with post hoc
Tukey’s test. Probabilities of event-free survival were obtained by
Kaplan–Meier analysis among the 3 or 4 AS subgroups and compared
using a 2-sided log-rank test. The impact of group classiﬁcation on
event-free survival was assessed using Cox proportional-hazard
models in univariate and multivariable analyses. Variables with a
univariate value of p < 0.1 were incorporated into multivariable
models. Because of collinearity, variables included in the multivariate
model were selected with special care. The group classiﬁcation was
entered into the model, and patients with MAS were considered as the
reference. p-values <0.05 were considered statistically signiﬁcant. All
statistical analyses were performed using commercial statistical
software (JMP, version 8, SAS Institute Inc., Cary, NC, USA).
Results
Patient characteristics
mong the 385 patients, 151 patients were diagnosed as
having MAS and 234 patients SAS (age, 76  8 years; 148 men).
Fig. 1. Study ﬂow chart. AS, aortic stenosis; iAVA, indexed aortic valve area; EF,
ejection fraction; HG, high gradient; LV, left ventricular; MAS, moderate AS; mean
PG, mean pressure gradient across the aortic valve; NFLG, normal-ﬂow, low-
gradient; PLFLG, paradoxical low-ﬂow, low-gradient; PLG, paradoxical low-
gradient; SAS, severe AS; SVi, stroke volume index.
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HG-SAS (n = 154). Finally, PLG-SAS patients were categorized as
NFLG-SAS (n = 61) and PLFLG-SAS (n = 19) (Fig. 1).
Demographic and echocardiographic data of the 3 AS groups
(MAS, PLG-SAS, and HG-SAS) and PLG-SAS subgroups (NFLG-SAS
and PLGLG-SAS) are shown in Table 1. Overall, most patients were
women and had hypertension. The PLG-SAS group was older than
the MAS group and had a higher proportion of men than the HG-
SAS group. Of note, 60% of PLG-SAS patients were asymptomatic, in
contrast to the signiﬁcantly lower percentage of asymptomatic
patients with HG-SAS. Moreover, each AS-related symptom was
less prevalent in the PLG-SAS patients than in the HG-SAS patients.
The prevalence of AS-related symptoms was similar between the
PLG-SAS patients and MAS patients. In the PLG-SAS subgroup,
demographic data were similar between the NFLG-SAS and PLFLG-
SAS groups, except for the lower prevalence of CAD in the PLFLG-
SAS patients.
Regarding the echocardiographic parameters, patients with
PLG-SAS had smaller LV chamber size and SV than those with HG-
SAS and MAS. PLG-SAS patients also had a lower LV mass index and
prevalence of concentric hypertrophy compared to HG-SAS
patients. Indexed AVA and ELCOs were the lowest in HG-SAS
patients, followed by PLG-SAS and MAS patients. The Zva in PLG-
SAS patients was higher than that in MAS patients, but similar to
that in HG-SAS patients. None of the enrolled patients had severe
diastolic dysfunction. Moreover, most AS patients (95%) had less-
than-moderate diastolic dysfunction. PLG-SAS patients had a less
severe diastolic function grade and lower LA volume as compared
to HG-SAS patients.
In the PLG-SAS subgroup, PLFLG-SAS patients showed lower
iAVA/ELCO and higher Zva than NFLG-SAS patients, and these
values were similar to those in HG-SAS patients.
Clinical outcomes
During a median follow-up of 15 months (range: 1–58
months), 31 patients experienced all-cause death, including
21 cardiac and 10 non-cardiac deaths. Further, 48 patients
developed MACE, including 21 cardiac deaths, 24 cases of
congestive heart failure requiring hospital admission, 2 cerebralinfarctions, and 1 ventricular ﬁbrillation. Overall, 176 patients
underwent AVR and were accordingly censored from analysis.
Overall survivals at 1 and 3 years in the total study population
were 96%  1% and 77%  6%, respectively.
Fig. 2A–C depicts the Kaplan–Meier survival analyses for all-
cause death, MACE, and culminated AVR rates among the HG-SAS,
PLG-SAS, and MAS patients. All-cause death and MACE rates in the
PLG-SAS group were signiﬁcantly lower than those in the HG-SAS
group and were similar to those in the MAS group (overall survival:
PLG-SAS: 1 year: 100  0%, 3 years: 91  6%; HG-SAS: 1 year:
91  4%, 3 years: 26  20%; MAS: 1 year: 98  2%, 3 years: 85  7%;
p = 0.001; Fig. 2A and MACE-free survival: PLG-SAS: 1 year: 94  4%,
3 years: 86%  7%; HG-SAS: 1 year: 82  6%, 3 years: 43  15%; MAS:
1 year: 97  2%, 3 years: 85  6%; p < 0.0001; Fig. 2B). The PLG-SAS
group had a lower AVR rate than the HG-SAS group (PLG-SAS: 1 year:
24  5%, 3 years: 33  7%; HG-SAS: 1 year: 66  4%, 3 years: 83  6%;
MAS: 1 year: 18  3%, 3 years: 33  7%; p < 0.0001; Fig. 2C).
Fig. 2D–F show the Kaplan–Meier analyses for all-cause death,
MACE, and cumulative AVR rates when PLG-SAS patients were
divided into PLFLG-SAS and NFLG-SAS groups. The PLFLG-SAS
group showed a better survival curve than the other groups
(PLFLG-SAS: overall survival: 100  0%, at 1 and 3 years; MACE-free
survival: 100  0%, at 1 and 3 years; NFLG-SAS: overall survival:
1 year: 100  0%, 3 years: 89  8%; MACE-free survival: 1 year:
93  5%, 3 years: 82  8%).
Fig. 3 represents the survival curve for MACE according to the
symptomatic status. There were no signiﬁcant differences in the
MACE rates among the 3 groups in symptomatic patients (PLG-
SAS: 72  14%; HG-SAS: 54  14%; MAS: 86  8% at 2 years;
p = 0.24; Fig. 3A). However, among asymptomatic patients, MACE-
free survival in the group of patients with PLG-SAS was signiﬁcantly
higher than that of the HG-SAS group, and it was nearly equivalent
to that of the MAS group (PLG-SAS: 96  4%; HG-SAS: 60  17%;
MAS: 92  4% at 2 years; p = 0.004; Fig. 3B). There were no
signiﬁcant differences in the MACE rate between the PLFLG-AS and
NFLG-SAS groups irrespective of symptom status (symptomatic:
PLFLG-SAS: 100  0%; NFLG-SAS: 69  15%; p = 0.55; Fig. 3C and
asymptomatic: PLFLG-SAS: 100  0%; NFLG-SAS: 92  4%; p = 0.55;
Fig. 3D).
Fig. 4 shows the effect of AVR on all-cause death. Although AVR
improved overall survival as compared with conservative treat-
ment in patients with HG-SAS (overall survival at 3 years: AVR:
85  5%; conservative: 24  18%; p = 0.04), there were no signiﬁcant
differences in the all-cause death rate between PLG-SAS patients
undergoing AVR or conservative treatment (AVR: 100  0%; conser-
vative: 89  7%; p = 0.38).
Predictors for event-free survival
Cox-hazard multivariate analysis indicated that advanced aging
and HG-SAS were independent predictors for all-cause death
(Table 2A). If the MAS group was set as a reference, the hazard ratio
(HR) of PLG-SAS was 0.47 [95% conﬁdence interval (CI) 0.07–1.95,
p = 0.32] in contrast to 3.37 (95% CI 1.24–9.74, p = 0.02) in HG-SAS.
Even when the PLG-SAS group was divided into PLFLG-SAS and
NFLG-SAS groups, neither of them was a signiﬁcant predictor of
future overall death (PLFLG-SAS: HR 0.01, p = 0.20; NFLG-SAS: HR
0.58, 95% CI 0.09–2.43, p = 0.48).
Table 2B presents the univariate and multivariate analyses for
predicting future MACE. Multivariate analysis veriﬁed that the HG-
SAS group was a strong independent positive predictor for MACE;
however, PLG-SAS and PLFLG-SAS groups were not signiﬁcant
predictors of MACE as compared with the MAS group (MAS as
reference, PLG-SAS: HR 0.77, 95% CI 0.20–1.95, p = 0.68; PLFLG-
SAS: HR = 0.01, p = 0.10; HG-SAS: HR 2.73, 95% CI 1.10–7.18,
p = 0.03).
Table 1
Patient characteristics and echocardiographic data.
Variable Overall analysis PLG-SAS subgroup analysis
MAS PLG-SAS HG-SAS p-value NFLG-SAS PLFLG-SAS p-value
(N = 151) (N = 80) (N = 154) (N = 61) (N = 19)
Age (years) 75  9 78  8* 76  9 0.045 79  7 76  9 0.31
Male 67 (44) 38 (48) 43 (28)*,y 0.002 26 (43) 12 (63) 0.13
Body surface area (m2) 1.50  0.18 1.51  0.16 1.46  0.18 0.05 1.51  0.16 1.54  0.15 0.44
Body mass index (BMI) (kg/m2) 22.7  3.6 22.9  3.5 22.4  3.6 0.56 22.9  3.6 22.7  3.4 0.82
Severe obesity (BMI >30 kg/m2) 6 (4) 3 (4) 6 (4) 0.99 3 (5) 0 (0) 1.00
Systolic blood pressure (mmHg) 142  24 137  22 136  21* 0.04 137  21 139  25 0.73
Diastolic blood pressure (mmHg) 73  13 73  12 70  15 0.09 72  11 77  14 0.10
Heart rate (beats/min) 71  16 69  17 72  14 0.37 69  14 70  25 0.78
Hypertension 117 (77) 61 (76) 104 (68) 0.10 47 (77) 14 (74) 0.68
Diabetes 49 (32) 33 (41) 39 (25) 0.05 24 (39) 9 (47) 0.57
Dyslipidemia 71 (47) 38 (48) 75 (49) 0.96 30 (49) 8 (42) 0.55
Atrial ﬁbrillation 14 (9) 14 (18) 23 (15) 0.14 8 (13) 6 (32) 0.08
History of smoking 59 (39) 21 (26) 34 (22)* 0.003 14 (23) 7 (37) 0.49
Coronary artery disease 51 (34) 29 (37) 33 (21) 0.02 25 (41) 4 (21) 0.02
Hemodialysis 22 (15) 7 (9) 15 (10) 0.31 6 (10) 1 (5) 1.00
Symptom
Asymptomatic 104 (69) 48 (60) 55 (36)*,y <0.0001 34 (56) 14 (74) 0.18
Chest pain/angina 13 (9) 6 (8) 37 (24)*,y 0.0001 5 (8) 1 (5) 0.65
Faintness/syncope 4 (3) 4 (5) 21 (14)*,y 0.0008 4 (7) 0 (0) 0.13
Dyspnea/history of heart failure 34 (22) 24 (30) 69 (45)* 0.0002 19 (31) 5 (26) 0.66
Hemoglobin (g/dL) 12  2 12  2 12  2 0.74 12  2 13  2 0.03
Glomerular ﬁltration rate (mL/min) 55  30 53  23 60  25 0.09 53  25 51  16 0.77
Serum BNP (pg/mL) 290  370 303  540 383  398 0.46 346  607 153  78 0.46
Medication
ACE inhibitor/ARB 84 (56) 45 (56) 68 (44) 0.08 32 (52) 13 (68) 0.22
Beta blocker 29 (19) 20 (25) 26 (17) 0.33 11 (18) 9 (47) 0.01
Diuretics 37 (25) 23 (29) 50 (32) 0.31 18 (30) 5 (26) 0.79
Statin 59 (39) 28 (35) 52 (34) 0.61 22 (36) 6 (32) 0.72
LV end-diastolic volume (mL) 84  30 70  26* 78  26 0.0014 72  26 63  27 0.20
LV end-diastolic volume index (mL/m2) 56  19 46  16* 53  17y <0.0001 48  16 41  17 0.12
LV ejection fraction (%) 64  9 64  9 65  9 0.41 65  9 62  10 0.26
Stroke volume index (mL/m2) 53  9 41  8* 49  11*,y <0.0001 45  6 30  4 <0.0001
LA volume index (mL/m2) 46  17 44  18 51  20y 0.035 45  18 43  20 0.69
E/e’ ratio 20  10 19  8 21  9 0.27 18  7 21  13 0.19
Diastolic dysfunction grade 0.01 0.59
Normal function 34 (23) 26 (33) 23 (15) 18 (30) 8 (42)
Mild dysfunction (Grade I) 109 (72) 49 (61) 124 (81) 39 (64) 10 (53)
Moderate dysfunction (Grade II) 8 (5) 5 (6) 7 (5) 4 (7) 1 (5)
LV mass index (g/m2) 122  36 111  29 135  41*,y <0.0001 114  29 105  35 0.24
Relative wall thickness (%) 53  10 53  11 58  14*,y <0.0001 53  10 57  14 0.15
LV geometry <0.0001 0.06
Normal geometry 10 (7) 10 (13) 5 (3) 7 (11) 3 (16)
Concentric remodeling 40 (27) 28 (35) 23 (15) 17 (28) 11 (58)
Concentric hypertrophy 85 (56) 40 (50) 120 (78) 35 (57) 5 (26)
Eccentric hypertrophy 16 (11) 2 (3) 6 (4) 2 (3) 0 (0)
Mean transvalvular ﬂow rate (mL/s) 282  89 198  45* 226  52*,y <0.0001 210  42 160  32 <0.0001
Peak aortic jet velocity (m/s) 3.6  0.7 3.6  0.4 4.9  0.7*,y <0.0001 3.6  0.3 3.3  0.6 0.0007
Mean gradient (mmHg) 32  14 29  7 63  29*,y <0.0001 31  7 25  7 0.002
AVA (cm2) 1.07  0.17 0.77  0.12* 0.63  0.16*,y <0.0001 0.80  0.10 0.68  0.14 <0.0001
Indexed AVA (cm2/m2) 0.72  0.07 0.51  0.07* 0.43  0.10*,y <0.0001 0.53  0.05 0.44  0.09 <0.0001
Valvulo-arterial impedance (mmHg/mL/m2) 3.1  0.9 4.2  1.4* 4.1  1.5* <0.0001 3.8  0.8 5.4  1.9 <0.0001
Energy loss coefﬁcient (cm2/m2) 0.95  0.15 0.62  0.10* 0.52  0.13*,y <0.0001 0.65  0.07 0.52  0.11 <0.0001
Values are represented as n (%) or mean  SD. AS, aortic stenosis; MAS, moderate AS; PLG-SAS, paradoxical low-gradient severe AS; HG-SAS, high-gradient severe AS; NFLG-
SAS, normal-ﬂow, low-gradient severe AS; PLFLG-SAS, paradoxical low-ﬂow, low-gradient severe AS; BNP, brain natriuretic peptide; ACE, angiotensin-converting enzyme; ARB,
angiotensin II receptor blocker; AVA, aortic valve area; LA, left atrial; LV, left ventricular.
* p < 0.05 vs. MAS.
y p < 0.05 vs. PLG-SAS.
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The present study demonstrated that Japanese PLFLG-SAS
patients have a better prognosis than those with HG-SAS, and
furthermore, their outcomes were similar to those of MAS patients,
which are similar to those of two previous reports [6,7], but
different from other reports from Europe and North America.
Although the pathophysiological differences in PLFLG-SAS be-
tween Japanese and Western populations could not be fully
discriminated in the present study, when considering the
discrepant outcomes of PLFLG-SAS between Japanese and Westernpatients, we hypothesized that the differences in the baseline
characteristics of the study population might have a major impact
on the pathophysiologies of PLG-SAS and PLFLG-SAS.
Clinical characteristics in PLFLG-SAS
A previous study revealed that PLFLG-SAS is characterized by
pronounced concentric LV hypertrophy (LVH), small LV cavity size,
and restrictive physiology [9]. However, our results demonstrated
that most Japanese PLFLG-SAS patients have a small LV chamber
but no concentric LVH. In fact, PLFLG-SAS patients showed a lower
Fig. 2. Kaplan–Meier analysis of all-cause death, major adverse cardio-cerebrovascular event (MACE)-free survival, and aortic valve replacement (AVR) rate. All-cause death,
MACE, and AVR rates among the 3 groups (HG-SAS, PLG-SAS, and MAS: A, B, and C, respectively) and among 4 groups (HG-SAS, PLFLG-SAS, NFLG-SAS, and MAS: D, E, and F,
respectively) divided according to the ﬂow-pressure proﬁles. The numerical scale below the graph represents the number of patients at risk who were followed up each year.
A p-value based on the log-rank test is shown in each analysis. AS, aortic stenosis; HG, high gradient; MAS, moderate AS; mean PG, mean pressure gradient across the aortic
valve; NFLG, normal-ﬂow, low-gradient; PLFLG, paradoxical low-ﬂow, low-gradient; PLG, paradoxical low-gradient; SAS, severe AS.
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recent study using cardiac magnetic resonance imaging (CMR)
[13], suggesting that PLFLG status may not always reﬂect an
advanced stage of SAS.
Table 3 shows the clinical features of PLFLG-SAS in the present
and previous studies. The prevalence of obesity, CAD, and heartfailure symptoms in this study were lower than those reported in
prior studies.
Western studies have shown that PLFLG-SAS patients had
higher BMI (27–32 kg/m2) and included a higher proportion (25–
47%) of obese patients [3,4,7,14–16]. However, the mean BMI in the
present study was 23 kg/m2 and none of the PLFLG-SAS patients
Fig. 3. MACE-free survival in patients with or without AS-related symptoms. MACE-free survival in patients with or without AS-related symptoms among 3 groups (A and B)
and among 4 groups (C and D). AS, aortic stenosis; HG, high gradient; MACE, major adverse cardio-cerebrovascular event; MAS, moderate AS; mean PG, mean pressure
gradient across the aortic valve; NFLG, normal-ﬂow, low-gradient; PLFLG, paradoxical low-ﬂow, low-gradient; PLG, paradoxical low-gradient; SAS, severe AS.
Fig. 4. Comparisons of overall survival between patients who received AVR or
conservative medical treatment (Cons.) in the HG-SAS and PLG-SAS groups. AVR,
aortic valve replacement; HG, high gradient; PLG, paradoxical low-gradient; SAS,
severe aortic stenosis.
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with LV afterload [17]. Moreover, obesity is not only a major
contributor to both diabetes and cardiovascular disease, but
typically involves additional components of the metabolic
syndrome, such as dyslipidemia and insulin resistance [18]. Insulin
resistance is a powerful predictor of progression to LVH in AS
patients [19]. In a leaner population of Japanese AS patients, the
progression of LVH to compensate the elevated LV afterload might
be indolent, which could cause a lower prevalence of excessive LVH
compared with similar Western patients.
The lower incidence of concomitant CAD (21%) might also be
associated with the better prognosis of Japanese patients with
PLFLG-SAS, while the prevalence of CAD in Western patients with
PLFLG-SAS is between 35% and 70% according to prior studies
[3,14–16,20]. Combined with AS and LVH, CAD reduces coronary
perfusion and ameliorates subendocardial ischemia, which causes
LV diastolic dysfunction via myocardial ﬁbrosis and impaired
relaxation.
Demographic differences between Japanese and Western
patients were also noted for less severe LV diastolic dysfunction
and a lower prevalence of symptomatic patients (Table 3). These
different baseline characteristics could be one potential cause for
the differences in the prognoses of PLFLG-SAS patients in Japan and
Western countries.
Table 2
Univariate and multivariate analyses of all-cause death and MACE.
Variables Univariate Multivariate model 1 Multivariate model 2
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
A: All-cause death
Age 1.06 1.01–1.11 0.009 1.10 1.03–1.17 0.002 1.10 1.03–1.18 0.002
LV ejection fraction 0.95 0.89–1.00 0.06 0.95 0.89–1.01 0.10 0.95 0.89–1.01 0.10
AS ﬂow-pressure proﬁle
MAS 1.00 1.00–1.00 NA 1.00 1.00–1.00 NA 1.00 1.00–1.00 NA
PLG-SAS 0.60 0.09–2.49 0.51 0.47 0.07–1.95 0.32 – – –
PLFLG-SAS 0.01 – 0.26 – – – 0.01 – 0.20
NFLG-SAS 0.76 – 0.72 – – – 0.58 – 0.48
HG-SAS 4.23 1.27–6.26 0.003 3.37 1.24–9.74 0.02 3.33 1.23–9.62 0.02
B: MACE
Age 1.14 1.08–1.21 <0.0001 1.13 1.07–1.20 <0.0001 1.13 1.07–1.20 <0.0001
Male 0.48 0.19–1.08 0.08 0.81 0.31–1.89 0.64 0.89 0.34–2.09 0.80
LA volume index (/10 mL/m2) 1.15 1.00–1.28 0.057 1.08 0.92–1.23 0.33 1.08 0.92–1.23 0.32
AS ﬂow-pressure proﬁle
MAS 1.00 Reference NA 1.00 1.00–1.00 NA 1.00 1.00–1.00 NA
PLG-SAS 1.10 0.29–3.49 0.88 0.77 0.20–1.95 0.68 – – –
PLFLG-SAS 0.01 – 0.21 – – – 0.01 – 0.10
NFLG-SAS 1.42 – 0.57 – – – 1.09 – 0.90
HG-SAS 4.42 1.87–11.2 <0.001 2.73 1.10–7.18 0.03 2.74 1.11–7.22 0.03
AS, aortic stenosis; MAS, moderate AS; PLG-SAS, paradoxical low-gradient severe AS; HG-SAS, high-gradient severe AS; LA, left atrial; LV, left ventricular; MACE, major
adverse cardio-cerebrovascular event; NFLG-SAS, normal-ﬂow, low-gradient severe AS; PLFLG-SAS, paradoxical low-ﬂow, low-gradient severe AS; CI, conﬁdence interval;
HR, hazard ratio.
Table 3
Comparisons of clinical features of PLFLG-SAS.
First author Ozkan [15] Clavel [3] Mehrotra [16] Melis [20] Eleid [14] Yamashita
Number of patients N = 1588 N = 805 N = 256 N = 363 N = 1704 N = 385
Study design Prospective Retrospective Retrospective Retrospective Retrospective Retrospective
Countries US Canada US Spain US Japan
Demographic data of PLFLG-SAS
Proportion of PLFLG-SAS to overall SAS (%) 9 28 15 12 3 8
Age (years) 78  9 74  12 82  10 78  5 77  12 76  9
Male (%) 53 49 74 41 66 63
Body surface area (m2) 1.88  0.25 1.80  0.24 1.75  0.3 1.74 2.01  0.24 1.54  0.15
Body mass index (kg/m2) 28  7 27  6 27  8 27 32  8 23  3
Obesity (%) – 25 – – 47 0
Coronary artery disease (%) 73 64 34 70 43 21
AS related symptom
NYHA class 2 58 78 45 – 60 26
NYHA class 3 34 56 29 – – –
Mean follow up 28  24 mo 4.2  2.4 y 36 mo 26.1 mo 2.3  1.9 y 15 mo
Underwent AVR during follow-up (%) 47 44 45 53 21
All-cause death rate (%) 40 36 42 31 40 0
Values are represented as mean  SD. AVR, aortic valve replacement; NYHA, New York Heart Association; PLFLG-SAS, paradoxical low-ﬂow, low-gradient severe aortic stenosis.
Fig. 5. Receiver-operating characteristics (ROC) curves for predicting MACE or AVR.
ROC curves of peak aortic velocity, mean gradient, indexed AVA, and SV index
measured by Doppler and Simpson method. AVA, aortic valve area; AVR, aortic valve
replacement; MACE, major adverse cardio-cerebrovascular event; SV, stroke volume.
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We used a SVi of 35 mL/m2 as a cut-off value to deﬁne low-ﬂow
status. This cut-off value was derived from studies performed in
North American populations [3–7]. It is possible that the optimal
cut-off may differ for the Japanese population. Fig. 5 shows
receiver-operating characteristics curve analysis for predicting
MACE or AVR. Although peak aortic velocity, mPG, and iAVA had
higher sensitivity and speciﬁcity for predicting future MACE or
AVR, SVi (Doppler or Simpson) could not predict MACE or AVR in
the study population. These results suggest that the prognostic
value of SVi might be limited because of the lower proportion of
low-ﬂow SAS patients with severe diastolic dysfunction in the
Japanese population.
Risk stratiﬁcation of Japanese patients with PLFLG-SAS
Although most Japanese PLFLG-SAS patients have a benign
prognosis, some patients could show malignant prognosis [3,4]. In
addition to conventional echocardiographic parameters, a multi-
disciplinary assessment should be performed for the risk
E. Yamashita et al. / Journal of Cardiology 65 (2015) 360–368 367stratiﬁcation of Japanese PLFLG-SAS patients. Projected AVA
derived from stress echocardiography [21], global longitudinal
strain measured by speckle-tracking echocardiography [22,23],
higher aortic valve calciﬁcation load by computed tomography and
LV remodeling, and ﬁbrosis by CMR could potentially discriminate
true-severe PLFLG AS from pseudo-severe PLFLG AS [13,24].
Clinical implications
As shown in Fig. 4, there was no clear beneﬁt of AVR on future
mortality in Japanese PLG-SAS patients, which indicates that
surgical indications for AVR in PLFLG-SAS should be considered
more carefully in Japanese patients than in Western patients.
Recent European guidelines recommend that patients with
symptomatic PLFLG-SAS should undergo surgical AVR after careful
conﬁrmation of stenosis severity [1]. Since it is sometimes difﬁcult
to verify that an observed symptom is solely related to AS, this
recommendation should be followed with caution. It may not
always be appropriate in patients of all ethnicities, especially in
patients with smaller body size or lower prevalence of obesity, as
in Asian-Paciﬁc populations. A worldwide survey concerning
ethnic variations in the prognoses of PLFLG-SAS should be assessed
in future studies.
Limitations
The present study has certain limitations. First, the retrospec-
tive enrollment of the study population could have produced a
selection bias, although this was a multicenter study. Moreover,
the number of PLFLG-SAS patients might be too small to assess the
clinical outcomes. Thus, prospective multicenter studies are
required to validate our results. Second, the AVR rate differed
between PLG-SAS and HG-SAS patients. However, if most PLFLG-
SAS patients have a malignant prognosis, lower AVR referral rates
would increase MACE or overall death rates. Nevertheless, the
lower death rate in PLG-SAS and PLFLG-SAS patients could be
evidence of better prognoses in these patients. Third, the
symptomatic status assessed in this study may not have been
accurate due to the lack of standardization in history taking and
the absence of exercise tests for revealing the actual symptomatic
status. Lastly, although this was a multicenter study, the
echocardiographic data were reported by each site and there
was no central (CoreLab) analysis. However, all the doctors and
sonographers from each institute who performed the echocardio-
graphic analysis attended the same training course regarding
standardized echocardiographic measurements, and they
remained blind to the patients’ data and prognoses.
Conclusions
In Japanese SAS patients, the prognoses of PLG-SAS and PLFLG-
SAS were clearly better than that of HG-SAS; furthermore, their
prognoses were similar to that of MAS patients. These results
suggest that there might exist certain differences in the prognoses
of PLG-SAS and PLFLG-SAS between patients from Japan and
Western countries.
Funding
This research received no grant from any funding agency in the
public, commercial, or not-for-proﬁt sectors.
Disclosure
The authors declare that there is no conﬂict of interest.Acknowledgments
None.
References
[1] Vahanian A, Alﬁeri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgart-
ner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Iung B,
Lancellotti P, Pierard L, Price S, et al. Guidelines on the management of valvular
heart disease (version 2012). Eur Heart J 2012;33:2451–96.
[2] Minners J, Allgeier M, Gohlke-Baerwolf C, Kienzle RP, Neumann FJ, Jander N.
Inconsistent grading of aortic valve stenosis by current guidelines: haemo-
dynamic studies in patients with apparently normal left ventricular function.
Heart 2010;96:1463–8.
[3] Clavel MA, Dumesnil JG, Capoulade R, Mathieu P, Senechal M, Pibarot P.
Outcome of patients with aortic stenosis, small valve area, and low-ﬂow,
low-gradient despite preserved left ventricular ejection fraction. J Am Coll
Cardiol 2012;60:1259–67.
[4] Lancellotti P, Magne J, Donal E, Davin L, O’Connor K, Rosca M, Szymanski C,
Cosyns B, Pierard LA. Clinical outcome in asymptomatic severe aortic stenosis:
insights from the new proposed aortic stenosis grading classiﬁcation. J Am Coll
Cardiol 2012;59:235–43.
[5] Hachicha Z, Dumesnil JG, Bogaty P, Pibarot P. Paradoxical low-ﬂow, low-
gradient severe aortic stenosis despite preserved ejection fraction is asso-
ciated with higher afterload and reduced survival. Circulation 2007;115:
2856–64.
[6] Maes F, Boulif J, Pierard S, de Meester C, Melchior J, Gerber B, Vancraeynest D,
Pouleur AC, Lazam S, Pasquet A, Vanoverschelde JL. Natural history of para-
doxical low gradient severe aortic stenosis. Circ Cardiovasc Imaging
2014;7:714–22.
[7] Jander N, Minners J, Holme I, Gerdts E, Boman K, Brudi P, Chambers JB, Egstrup
K, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Rossebo A, Pedersen TR,
Skjaerpe T, et al. Outcome of patients with low-gradient severe aortic stenosis
and preserved ejection fraction. Circulation 2011;123:887–95.
[8] Population Division of the United Nations, Department of Economic and Social
Affairs. World population prospects: the 2012 revision. New York: United
Nations; 2012.
[9] Pibarot P, Dumesnil JG. Low-ﬂow, low-gradient aortic stenosis with normal
and depressed left ventricular ejection fraction. J Am Coll Cardiol
2012;60:1845–53.
[10] Baumgartner H, Hung J, Bermejo J, Chambers JB, Evangelista A, Grifﬁn BP, Iung
B, Otto CM, Pellikka PA, Quin˜ones M. Echocardiographic assessment of valve
stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocar-
diogr 2009;22:1–23.
[11] Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA,
Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT,
Sutton MS, Stewart WJ. Recommendations for chamber quantiﬁcation: a
report from the American Society of Echocardiography’s Guidelines and
Standards Committee and the Chamber Quantiﬁcation Writing Group,
developed in conjunction with the European Association of Echocardiogra-
phy, a branch of the European Society of Cardiology. J Am Soc Echocardiogr
2005;18:1440–63.
[12] Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner
AD, Flachskampf FA, Pellikka PA, Evangelista A. Recommendations for the
evaluation of left ventricular diastolic function by echocardiography. J Am Soc
Echocardiogr 2009;22:107–33.
[13] Barone-Rochette G, Pierard S, Seldrum S, de Meester de Ravenstein C, Melchior
J, Maes F, Pouleur AC, Vancraeynest D, Pasquet A, Vanoverschelde JL, Gerber BL.
Aortic valve area, stroke volume, left ventricular hypertrophy, remodeling, and
ﬁbrosis in aortic stenosis assessed by cardiac magnetic resonance imaging:
comparison between high and low gradient and normal and low ﬂow aortic
stenosis. Circ Cardiovasc Imaging 2013;6:1009–17.
[14] Eleid MF, Sorajja P, Michelena HI, Malouf JF, Scott CG, Pellikka PA. Flow-
gradient patterns in severe aortic stenosis with preserved ejection fraction:
clinical characteristics and predictors of survival. Circulation 2013;128:
1781–9.
[15] Ozkan A, Hachamovitch R, Kapadia SR, Tuzcu EM, Marwick TH. Impact of aortic
valve replacement on outcome of symptomatic patients with severe aortic
stenosis with low gradient and preserved left ventricular ejection fraction.
Circulation 2013;128:622–31.
[16] Mehrotra P, Jansen K, Flynn AW, Tan TC, Elmariah S, Picard MH, Hung J.
Differential left ventricular remodelling and longitudinal function distin-
guishes low ﬂow from normal-ﬂow preserved ejection fraction low-gradient
severe aortic stenosis. Eur Heart J 2013;34:1906–14.
[17] de Simone G, Devereux RB, Roman MJ, Alderman MH, Laragh JH. Relation of
obesity and gender to left ventricular hypertrophy in normotensive and
hypertensive adults. Hypertension 1994;23:600–6.
[18] Klein S, Burke LE, Bray GA, Blair S, Allison DB, Pi-Sunyer X, Hong Y, Eckel RH.
Clinical implications of obesity with speciﬁc focus on cardiovascular disease: a
statement for professionals from the American Heart Association Council on
Nutrition, Physical Activity, and Metabolism: endorsed by the American
College of Cardiology Foundation. Circulation 2004;110:2952–67.
[19] Capoulade R, Clavel MA, Dumesnil JG, Chan KL, Teo KK, Tam JW, Cote N,
Mathieu P, Despres JP, Pibarot P. Insulin resistance and LVH progression in
E. Yamashita et al. / Journal of Cardiology 65 (2015) 360–368368patients with calciﬁc aortic stenosis: a substudy of the ASTRONOMER trial.
JACC Cardiovasc Imaging 2013;6:165–74.
[20] Melis G, Frontera G, Caldentey G, Sahuquillo A, Fernandez-Palomeque C,
Forteza JF, Bethencourt A, Saez-Ibarra JI, Bonnin O. Systolic volume index
by Doppler echocardiography is an useful marker for stratiﬁcation and prog-
nostic evaluation in patients with severe aortic stenosis and preserved ejection
fraction. Rev Esp Cardiol 2013;66:261–8.
[21] Clavel MA, Ennezat PV, Marechaux S, Dumesnil JG, Capoulade R, Hachicha Z,
Mathieu P, Bellouin A, Bergeron S, Meimoun P, Arsenault M, Le Tourneau T,
Pasquet A, Couture C, Pibarot P. Stress echocardiography to assess stenosis
severity and predict outcome in patients with paradoxical low-ﬂow, low-gradient
aortic stenosis and preserved LVEF. JACC Cardiovasc Imaging 2013;6:175–83.[22] Sato K, Seo Y, Ishizu T, Takeuchi M, Izumo M, Suzuki K, Yamashita E, Oshima S,
Akashi YJ, Otsuji Y, Aonuma K. Prognostic value of global longitudinal strain in
paradoxical low-ﬂow, low-gradient severe aortic stenosis with preserved
ejection fraction. Circ J 2014;78:2750–9.
[23] Lee HF, Hsu LA, Chan YH, Wang CL, Chang CJ, Kuo CT. Prognostic value of global
left ventricular strain for conservatively treated patients with symptomatic
aortic stenosis. J Cardiol 2013;62:301–6.
[24] Clavel MA, Messika-Zeitoun D, Pibarot P, Aggarwal SR, Malouf J, Araoz PA,
Michelena HI, Cueff C, Larose E, Capoulade R, Vahanian A, Enriquez-Sarano M.
The complex nature of discordant severe calciﬁed aortic valve disease grading:
new insights from combined Doppler echocardiographic and computed to-
mographic study. J Am Coll Cardiol 2013;62:2329–38.
